Inappropriate Vancomycin Prescribing Based on Criteria from the Centers for Disease Control and Prevention

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

Volumn 15, Issue 5, 1995, Pages 579-585

  Johnson, Steven V ^a,b   Hoey, Lori L ^a,b   Vance‐Bryan, Kyle ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b REGIONS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; COLITIS; CRITICAL ILLNESS; DRUG CHOICE; ENDOCARDITIS; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; PENICILLIN RESISTANCE; PRACTICE GUIDELINE; PRESCRIPTION; PROSTHESIS;

ADULT; AGED; ANTIBIOTICS, GLYCOPEPTIDE; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); COMPARATIVE STUDY; DRUG RESISTANCE, MICROBIAL; DRUG UTILIZATION; FEMALE; HUMAN; MALE; MIDDLE AGE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; RETROSPECTIVE STUDIES; UNITED STATES; VANCOMYCIN;

EID: 0029089439     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/j.1875-9114.1995.tb02866.x     Document Type: Article

References (42)

1. Multiple‐antibiotic‐resistant pathogenic bacteria
2. Can antibiotic resistance be controlled [editorial]
3. Health and economic impacts of antimicrobial resistance
4. Problems and dilemmas of antimicrobial resistance
5. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy
6. The crisis in antibiotic resistance
7. Emerging problems of antimicrobial resistance
8. Resistant gram‐positive organisms
9. Co‐transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Stophylococcus aureus
10. The epidemiology of intravenous vancomycin usage in a university hospital
11. Pharmacist interventions to improve prescribing of vancomycin and tobramycin
12. Vancomycin cost containment through a therapeutic and pharmacokinetic drug monitoring service
13. Drug utilization review in a teaching hospital: experience with vancomycin
14. Retrospective evaluation of vancomycin use in a university hospital
15. Nosocomial enterococci resistant to vancomycin—United States, 1989–1993
16. Transferable vancomycin and teicoplanin resistance in Enterococcus faecium
17. Community‐acquired pneumonia requiring hospitalization: 5‐year prospective study
18. Aetiology, outcome and prognostic factors in community‐acquired pneumonia requiring hospitalization
19. Antimicrobial resistance in Streptococcus pneumoniae: an overview
20. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain 1979–1988
21. Extremely high incidence of antibiotic resistance in clinical isolates of Streptococcus pneumoniae in Hungary
22. Emergence of drug‐resistant pneumococcal infections in the United States
23. Resistance to penicillin and non‐beta‐lactam antibiotics of Streptococcus pneumoniae at a children's hospital
24. Criteria for use of intravenous vancomycin for treatment of infections
25. Evidence‐based medicine
26. Is antimicrobial resistance in hospital microorganisms related to antibiotic use
27. Trends in antibiotic utilization and bacterial resistance: report of the national nosocomial resistance surveillance group
28. The current and future impact of antimicrobial resistance among nosocomial bacterial pathogens
29. Aminoglycoside resistance in gram‐negative bacilli during increased amikacin use
30. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital
31. Right‐sided Staphylococcus aureus endocarditis in intravenous drug abusers: two‐week combination therapy
32. Staphylococcus aureus and vancomycin: the sequel
33. Vancomycin therapy for methicillin‐resistant Staphylococcus aureus
34. Slow response to vancomycin or vancomycin plus rifampin in methicillin‐resistant Staphylococcus aureus endocarditis
35. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users
36. Comparative efficacy of daptomycin, vancomycin, and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination
37. Recommendations for preventing the spread of vancomycin resistance